References
- 1. Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712-1723. doi: 10.1182/blood-2013-04-460121.10.1182/blood-2013-04-460121
- 2. Abdol Razak NB, Jones G, Bhandari M, et al. Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment. Cancers. 2018;10:380. doi: 10.3390/cancers10100380.10.3390/cancers10100380
- 3. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;66:458-464. doi: 10.1001/archinte.166.4.458.10.1001/archinte.166.4.458
- 4. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850. doi: 10.1056/NEJM200012213432504.10.1056/NEJM200012213432504
- 5. Wójtowicz M, Rękas-Wójcik A, Lipa A, et al. Thrombotic complications – prevention and treatment of venous thromboembolism in cancer patients. Journal of Pre-Clinical and Clinical Research. 2012;6:84-87.
- 6. Streiff MB, Holmstrom B, Angelini D, et al. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018;16:1289-1303. doi: 10.6004/jnccn.2018.0084.10.6004/jnccn.2018.0084
- 7. Navi BB, Reiner AS, Kamel H, et al. Risk of Arterial Thromboembolism in Patients With Cancer. J Am Coll Cardiol. 2017;70:926-938. doi: 10.1016/j.jacc.2017.06.047.10.1016/j.jacc.2017.06.047
- 8. Levi M. Management of cancer-associated disseminated intravascular coagulation. Thrombo Res. 2016;140:S66-S70. doi: 10.1016/S0049-3848(16)30101-3.10.1016/S0049-3848(16)30101-3
- 9. Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016;10:649. doi: 10.3332/ecancer.2016.649.10.3332/ecancer.2016.649
- 10. Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res. 2010;125:S1-S7. doi: 10.1016/S0049-3848(10)00227-6.10.1016/S0049-3848(10)00227-6
- 11. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-4907. doi: 10.1182/blood-2007-10-116327.10.1182/blood-2007-10-116327238412418216292
- 12. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377-5382. doi: 10.1182/blood-2010-02-270116.10.1182/blood-2010-02-27011620829374
- 13. Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7:291-292. doi: 10.1007/s11739-012-0784-y.10.1007/s11739-012-0784-y22547369
- 14. Pelzer U, Sinn M, Stieler J, et al. Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? Dtsch Med Wochenschr. 2013;138:2084-2088. doi: 10.1055/s-0033-1349608.10.1055/s-0033-134960824085361
- 15. Muñoz Martín AJ, Ortega I, Font C, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118:1056-1061. doi: 10.1038/s41416-018-0027-8.10.1038/s41416-018-0027-8593110329588512
- 16. Khorana AA, DeSancho MT, Liebman H, et al. Prediction and Prevention of Cancer-Associated Thromboembolism. Oncologist. 2021;26:e2-e7. doi: 10.1002/onco.13569.10.1002/onco.13569779420333274815
- 17. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Amer J Med. 2006;119:60-68. doi: 10.1016/j.amjmed.2005.06.058.10.1016/j.amjmed.2005.06.05816431186
- 18. Dickmann B, Ahlbrecht J, Pabinger I. Regional lymph node metastases are a strong risk factor for venous thromboembolism: Results from the Vienna Cancer and Thrombosis Study. Haematologica. 2013;98:1309-1314. doi: 10.3324/haematol.2012.073338.10.3324/haematol.2012.073338372991323585523
- 19. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-722. doi: 10.1001/jama.293.6.715.10.1001/jama.293.6.71515701913
- 20. Næss IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost. 2007;5:692-699. doi: 10.1111/j.1538-7836.2007.02450.x.10.1111/j.1538-7836.2007.02450.x17367492
- 21. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339-2346. doi: 10.1002/cncr.23062.10.1002/cncr.2306217918266
- 22. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncology. 2006;24:484-490. doi: 10.1200/JCO.2005.03.8877.10.1200/JCO.2005.03.887716421425
- 23. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. Ann Surg. 2006;243:89-95. doi: 10.1097/01.sla.0000193959.44677.48.10.1097/01.sla.0000193959.44677.48144997916371741
- 24. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost. 2010;8:114-120. doi: 10.1111/j.1538-7836.2009.03680.x.10.1111/j.1538-7836.2009.03680.x19889150
- 25. Connolly GC, Khorana AA, Kuderer NM, et al. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res. 2010;126:113-118. doi: 10.1016/j. thromres.2010.05.012.
- 26. Dai H, Zhou H, Sun Y, et al. D-dimer as a potential clinical marker for predicting metastasis and progression in cancer. Biomed Rep. 2018;9:453-457. doi: 10.3892/br.2018.1151.10.3892/br.2018.1151620104730402229
- 27. Sallah S, Husain A, Sigounas V, et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res. 2004;10:7238-7243. doi: 10.1158/1078-0432.CCR-04-0445.10.1158/1078-0432.CCR-04-044515534097
- 28. Riondino S, Ferroni P, Zanzotto FM, et al. Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers (Basel). 2019;11:95. doi: 10.3390/cancers11010095.10.3390/cancers11010095635624730650562
- 29. Arpaia G, Carpenedo M, Verga M, et al. D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis. 2009;20:170-175. doi: 10.1097/MBC.0b013e32831bc2de.10.1097/MBC.0b013e32831bc2de19276795
- 30. Kondo S, Sasaki M, Hosoi H, et al. Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma. Oncotarget. 2018;9:16883-16890. doi: 10.18632/oncotarget.24721.10.18632/oncotarget.24721590829229682191
- 31. Park K, Ryoo BY, Ryu MH, et al. Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study. World J Gastrointest Oncol. 2017;9:176-183. doi: 10.4251/wjgo.v9.i4.176.10.4251/wjgo.v9.i4.176539030328451065
- 32. Wu J, Fu Z, Liu G, et al. Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis. Medicine. 2017;96:e7062. doi: 10.1097/MD.0000000000007062.10.1097/MD.0000000000007062548419128640083
- 33. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112:2703-2708. doi: 10.1182/blood-2008-02-142422.10.1182/blood-2008-02-14242218539899
- 34. Di Nisio M, Ferrante N, De Tursi M, et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost. 2010;104:1049-1054. doi: 10.1160/TH10-05-0277.10.1160/TH10-05-027720806119
- 35. Khorana AA, Dalal M, Lin J, et al. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119:648-655. doi: 10.1002/cncr.27772.10.1002/cncr.2777222893596
- 36. Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005;103:994-999. doi: 10.1002/cncr.20893.10.1002/cncr.2089315666321
- 37. Cunningham D, Starling N, Rao S, et al. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med. 2008;358:36-46. doi: 10.1056/NEJMoa073149.10.1056/NEJMoa07314918172173
- 38. John AH. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464-474. doi: 10.1038/nrcardio.2015.83.10.1038/nrcardio.2015.83462429826076949
- 39. Lee AYY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24:1404-1408. doi: 10.1200/JCO.2005.03.5600.10.1200/JCO.2005.03.560016549834
- 40. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;00:3484-3488. doi: 10.1182/blood-2002-01-0108.10.1182/blood-2002-01-010812393647
- 41. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153. doi: 10.1056/NEJMoa025313.10.1056/NEJMoa02531312853587
- 42. Lee AYY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314:677-686. doi: 10.1001/jama.2015.9243.10.1001/jama.2015.924326284719
- 43. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE Disease: CHEST guideline and expert panel eport. Chest. 2016;149:315-352. doi: 10.1016/j.chest.2015.11.026.10.1016/j.chest.2015.11.026
- 44. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med. 2002;162:1729-1735. doi: 10.1001/archinte.162.15.1729.10.1001/archinte.162.15.1729
- 45. Deitcher SR, Kessler CM, Merli G, et al. ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006; 12:389-396. doi: 10.1177/1076029606293692.10.1177/1076029606293692
- 46. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119:1062-1072. doi: 10.1016/j.amjmed.2006.02.022.10.1016/j.amjmed.2006.02.022
- 47. Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452-e466. doi: 10.1016/S1470-2045(16)30369-2.10.1016/S1470-2045(16)30369-2
- 48. Farge D, Frere C, Connors JM, et al. International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20:e566-e581. doi: 10.1016/S1470-2045(19)30336-5.10.1016/S1470-2045(19)30336-5
- 49. Hakoum MB, Kahale LA, Tsolakian IG, et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;1:CD006649. doi: 10.1002/14651858.CD006649.pub7.10.1002/14651858.CD006649.pub7638933929363105
- 50. Robertson L, Jones LE. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev. 2017;2:CD001100. doi: 10.1002/14651858. CD001100.pub4.10.1002/14651858
- 51. Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38:496-520. doi: 10.1200/JCO.19.01461.10.1200/JCO.19.0146131381464
- 52. Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018;39:4208-4218. doi: 10.1093/eurheartj/ehx003.10.1093/eurheartj/ehx00328329262
- 53. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615-624. doi: 10.1056/NEJMoa1711948.10.1056/NEJMoa171194829231094
- 54. Young AM, Marshall A, Thirlwall J, et al: Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017-2023. doi: 10.1200/JCO.2018.78.8034.10.1200/JCO.2018.78.803429746227
- 55. Li A, Garcia DA, Lyman GH, et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019;173:158-163. doi: 10.1016/j.thromres.2018.02.144.10.1016/j.thromres.2018.02.144611965529506866
- 56. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35:3240-3261. doi: 10.1200/JCO.2017.74.4789.10.1200/JCO.2017.74.478928759346
- 57. Muñoz Martín AJ, Gallardo Díaz E, García Escobar I, et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer Clin Transl Oncol. 2020;22:171-186. doi: 10.1007/s12094-019-02263-z.10.1007/s12094-019-02263-z31981080
- 58. Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: The DALTECAN study. J Thromb Haemost. 2015;13:1028-1035. doi: 10.1111/jth.12923.10.1111/jth.1292325827941
- 59. Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, et al. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res. 2017;157:90-96. doi: 10.1016/j. thromres.
- 60. Zurawska U, Parasuraman S, Goldhaber SZ. Prevention of pulmonary embolism in general surgery patients. Circulation. 2007;115:e302-e307. doi: 10.1161/CIRCULATIONAHA.
- 61. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975-980. doi: 10.1056/NEJMoa012385.10.1056/NEJMoa01238511919306
- 62. Bustos Merlo AB, Arcelus Martınez JI, Turiño Luque JD, et al. Form of presentation, natural history and course of postoperative venous thromboembolism in patients operated on for pelvic and abdominal cancer. Analysis of the RIETE registry. Cir Esp. 2017;95:328-334. doi: 10.1016/j. ciresp.2017.05.006.
- 63. Fagarasanu A, Alotaibi GS, Hrimiuc R, et al. Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:1422-1430. doi: 10.1245/s10434-016-5127-1.10.1245/s10434-016-5127-126887853
- 64. Di Nisio M, Porreca E, Candeloro M, et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016;12:CD008500. doi: 10.1002/14651858.CD008500.pub4.10.1002/14651858.CD008500.pub4646393727906452
- 65. Khorana AA, Francis CW, Kuderer NM, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thromb Res. 2017;151:89-95. doi: 10.1016/j.thromres.2017.01.009.10.1016/j.thromres.2017.01.00928139259
- 66. Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720-728. doi: 10.1056/NEJMoa1814630.10.1056/NEJMoa181463030786186
- 67. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711-719. doi: 10.1056/NEJMoa1814468.10.1056/NEJMoa181446830511879
- 68. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21:3665-3675. doi: 10.1200/JCO.2003.08.008.10.1200/JCO.2003.08.00814512399
- 69. Kahale LA, Tsolakian IG, Hakoum MB, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev. 2018;6:CD006468. doi: 10.1002/14651858. CD006468.pub6.10.1002/14651858
- 70. Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24:1404-1408. doi: 10.1200/JCO.2005.03.5600.10.1200/JCO.2005.03.560016549834
- 71. Saber W, Moua T, Williams EC, et al. Risk factors of catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2011;9:312-319. doi: 10.1111/j.1538-7836.2010.04126.x.10.1111/j.1538-7836.2010.04126.x428279621040443
- 72. Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (the Catheter study). J Thromb Haemost. 2007;5:1650-1653. doi: 10.1111/j.1538-7836.2007.02613.x.10.1111/j.1538-7836.2007.02613.x17488349
- 73. Kreuziger LB, Ageno W, Lee A. Management of incidental splanchnic vein thrombosis in cancer patients. Hematology Am Soc Hematol Educ Program. 2014;2014:318-320. doi: 10.1182/asheducation-2014.1.318.10.1182/asheducation-2014.1.31825696872
- 74. Ihaddadene R, Le Gal G, Delluc A, et al. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thromb Res. 2014;134:93-95. doi: 10.1016/j.thromres.2014.04.028.10.1016/j.thromres.2014.04.02824835673
- 75. Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7:760-765. doi: 10.1111/j.1538-7836.2009.03326.x.10.1111/j.1538-7836.2009.03326.x19245418
- 76. Samuelson Bannow BR, Lee AYY, Khorana AA, et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review. Res Pract Thromb Haemost. 2018;2:664-669. doi: 10.1002/rth2.12111.10.1002/rth2.12111617871330349884